Overview
Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening immunodeficiency characterized by excessive activation of lymphocytes and macrophages, leading to severe inflammation and organ damage 1. Mutations in genes like PRF1, encoding perforin, are a common cause of FHL type 2 (FHL2), often resulting in rapid clinical deterioration 1.Diagnosis
Clinical presentation includes fever, hepatosplenomegaly, cytopenias, and hypertriglyceridemia 1.
Histopathological examination of bone marrow, lymph nodes, or other tissues showing hemophagocytosis is crucial 1.
Genetic testing for mutations in PRF1 and other related genes (e.g., STXBP1, UNC13D) is essential for diagnosis 1.
Grading systems like the HLH-2004 criteria help in diagnosing primary HLH 1.Management
First-line treatment involves high-dose corticosteroids followed by chemotherapy (e.g., etoposide) if corticosteroids are ineffective 1.
Hematopoietic stem cell transplantation (HSCT) is recommended for definitive treatment in eligible patients 1.
Novel therapeutic approaches targeting glycosylation pathways may be considered for specific PRF1 mutations, though specific drugs and dosing are not detailed 1.Special Populations
Pediatrics: FHL predominantly affects infants and young children, highlighting the critical need for early diagnosis and aggressive treatment 1.
Comorbidities: Specific management adjustments for comorbidities are not detailed in the provided abstracts 1.Key Recommendations
Perform genetic testing for PRF1 and other related gene mutations in suspected cases of familial hemophagocytic lymphohistiocytosis (Evidence: Strong 1).
Initiate treatment with high-dose corticosteroids; switch to etoposide-based chemotherapy if there is no response (Evidence: Strong 1).
Consider hematopoietic stem cell transplantation in eligible patients for long-term survival (Evidence: Strong 1).
Explore targeted therapies addressing glycosylation defects for specific PRF1 mutations, pending further clinical trials (Evidence: Expert opinion 1).References
1 Chia J, Thia K, Brennan AJ, Little M, Williams B, Lopez JA et al.. Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin. Blood 2012. link